Successful Treatment of Metastatic Gallbladder Carcinoma with PD-L1 Expression by the Combination of PD-1 Inhibitor Plus Bevacizumab with Chemotherapy: A Case Report

References

• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Lamarca A, Ross P, Wasan HS, et al. Advanced intrahepatic cholangiocarcinoma: post Hoc analysis of the ABC-01, −02, and −03 Clinical Trials. J Natl Cancer Inst. 2020;112(2):200–210. doi:10.1093/jnci/djz071
   PubMedGoogle Scholar
• Zhu X, Zhang X, Hu X, et al. Survival analysis of patients with primary gallbladder cancer from 2010 to 2015: a retrospective study based on SEER data. Medicine. 2020;99(40):e22292. doi:10.1097/md.0000000000022292
   PubMed Web of Science ®Google Scholar
• Azizi AA, Lamarca A, Valle JW. Systemic therapy of gallbladder cancer: review of first line, maintenance, neoadjuvant and second line therapy specific to gallbladder cancer. Chin Clin Oncol. 2019;8(4):43. doi:10.21037/cco.2019.07.05
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281. doi:10.1056/NEJMoa0908721
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, Phase 3 study. Lancet Oncol. 2020;21(6):796–807. doi:10.1016/s1470-2045(20)30157-1
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, Phase 2 study. Lancet Oncol. 2020;21(5):671–684. doi:10.1016/s1470-2045(20)30109-1
   PubMed Web of Science ®Google Scholar
• Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: ready for “prime time” in biliary tract cancer. J Hepatol. 2020;73(1):170–185. doi:10.1016/j.jhep.2020.03.007
   PubMed Web of Science ®Google Scholar
• Subbiah V, Lassen U, Élez E, et al. Dabrafenib plus trametinib in patients with BRAF (V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21(9):1234–1243. doi:10.1016/s1470-2045(20)30321-1
   PubMed Web of Science ®Google Scholar
• Iyer RV, Pokuri VK, Groman A, et al. A multicenter Phase II study of gemcitabine, capecitabine, and bevacizumab for locally advanced or metastatic biliary tract cancer. Am J Clin Oncol. 2018;41(7):649–655. doi:10.1097/coc.0000000000000347
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Każarnowicz A, Karaseva N, et al. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. Ann Oncol. 2020;31(2):310–317. doi:10.1016/j.annonc.2019.10.021
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092. doi:10.1056/NEJMoa1801005
   PubMed Web of Science ®Google Scholar
• Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, Phase 3 study. Lancet. 2019;394(10212):1915–1928. doi:10.1016/s0140-6736(19)32591-7
   PubMed Web of Science ®Google Scholar
• André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–2218. doi:10.1056/NEJMoa2017699
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, Phase 3 trial. Lancet. 2021;398(10294):27–40. doi:10.1016/s0140-6736(21)00797-2
   PubMed Web of Science ®Google Scholar
• Tang S, Ning Q, Yang L, Mo Z, Tang S. Mechanisms of immune escape in the cancer immune cycle. Int Immunopharmacol. 2020;86:106700. doi:10.1016/j.intimp.2020.106700
   PubMed Web of Science ®Google Scholar
• Xin YJ, Hodge JP, Oliva C, Neftelinov ST, Hubbard-Lucey VM, Tang J. Trends in clinical development for PD-1/PD-L1 inhibitors. Nat Rev Drug Discov. 2020;19(3):163–164. doi:10.1038/d41573-019-00182-w
   PubMed Web of Science ®Google Scholar
• Vogel A, Bathon M, Saborowski A. Immunotherapies in clinical development for biliary tract cancer. Expert Opin Investig Drugs. 2021;30(4):351–363. doi:10.1080/13543784.2021.1868437
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Recent advances of immunotherapy for biliary tract cancer. Expert Rev Gastroenterol Hepatol. 2021;15(5):527–536. doi:10.1080/17474124.2021.1853527
   PubMed Web of Science ®Google Scholar
• Ricci AD, Rizzo A, Brandi G. Immunotherapy in biliary tract cancer: worthy of a second look. Cancer Control. 2020;27(3):1073274820948047. doi:10.1177/1073274820948047
   Web of Science ®Google Scholar
• Piha-Paul SA, Oh DY, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int j Cancer. 2020;147(8):2190–2198. doi:10.1002/ijc.33013
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opin Investig Drugs. 2021;30(4):343–350. doi:10.1080/13543784.2021.1897102
   PubMed Web of Science ®Google Scholar
• Oneda E, Abu Hilal M, Zaniboni A. Biliary tract cancer: current medical treatment strategies. Cancers. 2020;12(5):1237. doi:10.3390/cancers12051237
   PubMed Web of Science ®Google Scholar
• Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020;30(6):507–519. doi:10.1038/s41422-020-0337-2
   PubMed Web of Science ®Google Scholar
• Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325–340. doi:10.1038/nrclinonc.2018.29
   PubMed Web of Science ®Google Scholar
• Hack SP, Zhu AX, Wang Y. Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-L1 pathways: challenges and opportunities. Front Immunol. 2020;11:598877. doi:10.3389/fimmu.2020.598877
   PubMed Web of Science ®Google Scholar
• Bailly C, Thuru X, Quesnel B. Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times. NAR cancer. 2020;2(1):zcaa002. doi:10.1093/narcan/zcaa002
   PubMedGoogle Scholar
• Teng F, Meng X, Kong L, Yu J. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: a systematic review. Cancer Lett. 2018;414:166–173. doi:10.1016/j.canlet.2017.11.014
   PubMed Web of Science ®Google Scholar
• Kon E, Benhar I. Immune checkpoint inhibitor combinations: current efforts and important aspects for success. Drug Resist Updates. 2019;45:13–29. doi:10.1016/j.drup.2019.07.004
   PubMed Web of Science ®Google Scholar
• Pinter M, Jain RK, Duda DG. The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review. JAMA Oncol. 2021;7(1):113–123. doi:10.1001/jamaoncol.2020.3381
   PubMed Web of Science ®Google Scholar
• Chen DS, Hurwitz H. Combinations of bevacizumab with cancer immunotherapy. Cancer j. 2018;24(4):193–204. doi:10.1097/ppo.0000000000000327
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301. doi:10.1056/NEJMoa1716948
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127. doi:10.1056/NEJMoa1816714
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. Lancet Oncol. 2021;22(7):977–990. doi:10.1016/s1470-2045(21)00252-7
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer. Cancers. 2021;13(3):558. doi:10.3390/cancers13030558
   PubMed Web of Science ®Google Scholar